
## Optimizing Patient Adherence to Targeted Therapies in Renal Cell Carcinoma: Practical Management Strategies in the Second-Line Setting

Patricia A. Creel, BSN, RN, OCN®, CCRP



© Eraxion/iStockphoto

The current standard of care for treating metastatic renal cell carcinoma is sequential therapy with vascular endothelial growth factor—targeted agents (i.e., axitinib, bevacizumab, pazopanib, sorafenib, and sunitinib) and mammalian target of rapamycin inhibitors (i.e., everolimus and temsirolimus). To maximize adherence to and persistence with targeted therapy, which should help improve clinical benefit, a clear understanding of the tolerability profiles of these agents and implementation of early, appropriately aggressive adverse event (AE) prevention and management strategies are key. Active and aggressive AE management should improve the quality of life of patients during the course of their treatment. Nurses are in a unique position to educate patients on the potential AEs they may experience and their prevention and management. This

article reviews the safety and tolerability of currently available targeted therapies recommended for use in the second-line treatment setting, as well as their management in the context of maximizing clinical outcomes and patient quality of life.

Patricia A. Creel, BSN, RN, OCN®, CCRP, is a clinical research associate at Duke University Medical Center in Durham, NC. The author takes full responsibility for the content of the article. Editorial assistance was provided by Melanie Leiby, PhD, of ApotheCom, funded by Novartis Pharmaceuticals Corporation. The content of this article has been reviewed by independent peer reviewers to ensure that it is balanced, objective, and free from commercial bias. No financial relationships have been disclosed by the independent peer reviewers or editorial staff. Creel can be reached at patricia.creel@duke.edu, with copy to editor at CJONEditor@ ons.org. (Submitted March 2013. Revision submitted March 2014. Accepted for publication March 16, 2014.)

Key words: adverse event management; mammalian target of rapamycin; renal cell carcinoma; vascular endothelial growth factor receptor; tyrosine kinase inhibitor Digital Object Identifier: 10.1188/14.CJON.694-700

bout 63,920 new cases of kidney cancer are expected to be diagnosed in 2014 in the United States (American Cancer Society, 2014), with a median age at diagnosis of 64 years and a higher incidence in men (21 per 100,000 men versus 10.6 per 100,000 women) (Surveillance, Epidemiology, and End Results Program, 2014). About 90% of kidney cancers are renal cell carcinoma (RCC) (American Cancer Society, 2014), for which the five-year relative survival rate increased from 50% in 1975-1977 to 71% in 2001-2007 (Siegel, Naishadham, & Jemal, 2012). This likely resulted from the combined effects of earlier diagnosis and improved therapeutic options (Siegel et al., 2012). The evolution of molecularly targeted therapy has contributed to significant improvement in outcomes for the almost two-thirds of patients with RCC who are either diagnosed with metastatic RCC (mRCC) or experience relapse following surgery for localized disease (American Cancer Society, 2014; National Comprehensive Cancer Network [NCCN], 2014; Siegel et al., 2012). Targeted therapies approved for treating advanced RCC include the anti-vascular endothelial growth factor (VEGF) antibody bevacizumab (used

in combination with interferon alpha) (Escudier, Pluzanska, et al., 2007); the VEGF receptor tyrosine kinase inhibitors (VEGFr-TKIs) sunitinib, sorafenib, pazopanib, and axitinib (Escudier, Eisen, et al., 2007; Motzer et al., 2007; Rini, Escudier, et al., 2011; Sternberg et al., 2010); and the mammalian target of rapamycin (mTOR) inhibitors everolimus and temsirolimus (Hudes et al., 2007; Motzer et al., 2008). Despite the significant benefit provided by first-line therapies, they are noncurative, and patients ultimately develop resistance and show disease progression. Therefore, sequential treatment with targeted therapies is the current standard of care for treating mRCC (NCCN, 2014).

Although sequential treatment is recognized as the best option for maximizing disease control and survival in mRCC, the optimal therapeutic sequence is unknown (Porta et al., 2012). Given that the primary goals of second-line therapy are to control disease progression and maintain patient quality of life (NCCN, 2014), the choice of second-line therapy should be driven by efficacy, safety, and tolerability. This article reviews the safety and tolerability of available targeted therapies recommended for use as second-line treatment, as well as their